Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Northwest Biotherapeutics (NWBO) over the last 16 years, with Q3 2025 value amounting to $451000.0.

  • Northwest Biotherapeutics' Depreciation & Amortization (CF) rose 134.83% to $451000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 242.63%. This contributed to the annual value of $1.7 million for FY2024, which is 1436.07% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Depreciation & Amortization (CF) of $451000.0 as of Q3 2025, which was up 134.83% from $451000.0 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Depreciation & Amortization (CF) registered a high of $524000.0 during Q2 2022, and its lowest value of $68000.0 during Q1 2021.
  • Over the past 5 years, Northwest Biotherapeutics' median Depreciation & Amortization (CF) value was $416000.0 (recorded in 2023), while the average stood at $325315.8.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 375000.0% in 2021, then tumbled by 3320.61% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Depreciation & Amortization (CF) stood at $84000.0 in 2021, then surged by 278.57% to $318000.0 in 2022, then surged by 33.33% to $424000.0 in 2023, then increased by 3.07% to $437000.0 in 2024, then increased by 3.2% to $451000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $451000.0 in Q3 2025, compared to $451000.0 in Q2 2025 and $434000.0 in Q1 2025.